The impact of imiquimod on radiation-induced lung injury: Results of an experimental study Imiquimod attenuates radiation lung injury
Tarih
2019Yazar
ÇALIK, Mustafa
ÇALIK, Saniye Göknil
YAVAŞ, Güler
ÇELİK, Zeliha Esin
YAVAŞ, Çağdaş
SARGON, Mustafa Fevzi
ESME, Hıdır
Üst veri
Tüm öğe kaydını gösterÖzet
Aim: Radiation-induced lung injury (RILI) is a major dose-limiting
factor during thoracic irradiation. Imiquimod (Imq) is a heterocyclic
amine that has been shown to be effective in diseases related to
inflammation and fibrosis. In this study, we aimed to evaluate the
impact of Imiquimod on RILI. Material and Method: The study included 60
adult female Wistar-Albino rats (250-300 g). Rats were divided into 6
groups: Group (G) 1: control, G2: radiotherapy (RT) only, G3 and G4: 5
and 10 mg/kg Imq, G5 and G6 RT: plus 5 and 10 mg/kg Imq groups
respectively. A single dose of 15 Gray (Gy) RT was given to the lungs.
Imq was applied intraperitoneal. Results: The inflammation, fibrosis,
and transforming growth factor (TGF)-beta scores of the study groups
were significantly different at 6th and 16th week of RT (p < 0.001 for
all). At the 6th week of RT, inflammation, fibrosis, and TGF-beta scores
did not differ in both RT and non-RT groups. By the 16th week of RT
inflammation, fibrosis, and TGF-beta scores were significantly different
between G2 and G5, and G2 and G6. Electron microscopy findings supported
the results of the light microscopy. Discussion: Although Imq did not
improve pneumonitis phase, Imq attenuated radiation-induced lung
fibrosis. These findings should be clarified with further preclinical
and clinical studies.
Koleksiyonlar
DSpace@Karatay by Karatay University Institutional Repository is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 Unported License..